Targeted attenuation of liver fibrosis using microbubble-enhanced protease-activated receptor 1 chimeric antigen receptor T cells.
CAR T cells engineered to target fibrosis slow liver scarring in animal models, extending cell therapy beyond cancer to widespread fibrotic diseases.
This study demonstrates that CAR T cells targeting protease-activated receptor 1 (PAR1), combined with microbubble enhancement for hepatic delivery, attenuate liver fibrosis in preclinical models. The work extends CAR T cell therapy to non-malignant fibrotic disease, representing a novel therapeutic paradigm for a high-burden condition with limited disease-modifying options.
What the study was
- Study design
- Preclinical experimental study
- Population
- Liver fibrosis murine models and hepatic stellate cell lines
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Biomedicine & pharmacotherapy
Why it surfaced
Biomed Pharmacother; PAR1 CAR T for liver fibrosis extends CAR T beyond oncology; novel therapeutic paradigm; high-unmet-need application.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.